paramethadione
Trade name: Paradione
Small moleculeapproved
Approved
Jun 15, 1949
Paramethadione is an anticonvulsant in the oxazolidinedione class developed by the Abbott Laboratories, approved by the Food and Drug Administration in 1949 for the treatment of absence seizures, also called partial seizures. Paramethadione acts to reduce T-type calcium currents in thalamic neurons which has been proposed to underlie the 3-Hz spike-and-wave discharge seen on electroencephalogram (EEG) during absence seizures. — NCATS
Clinical trial activity
0 trials · 0 clinical orgs · 2 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Timeline
1940s
- Jun 15, 1949
Earliest FDA Approval
- Jun 15, 1949
AbbVie — NDA Secondary Org
Indications
Approved for
Mechanism of action
Approval history
- approvedJun 15, 1949
Chemistry & pharmacology
Loading structure…
SMILES
CCC1(C)OC(=O)N(C)C1=O- Mol. weight
- 157.1671 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaParamethadione ↗
- NCATSZ615FRW64N ↗
- ChEMBLCHEMBL1100 ↗
Also known as
- 5-ethyl-3,5-dimethyloxazolinedione
- isoethadione
- isoethadione
- paradione
- paradione
- paradione
- paradione
- parametadiona
- parametadiona
- parametadione
- parametadione
- parametadione
- paramethadione
- paramethadione
- paramethadione
- paramethadione
- paramethadione
- paramethadione
- paramethadione
- paramethadione
- paramethadione
- paramethadione
- paramethadione
- paramethadionum
- paramethadionum